GlassScriptPhysician profile
Colleen Buggs-Saxton
NPI 1750337135
$1,757.77
in general payments reported to CMS, 2019-2025
24 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $70.25 · 2021: $223 · 2022: $294 · 2023: $236 · 2024: $332 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $406.95 | 2019-2023 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $372.96 | 2020-2025 | |
| Medtronic Minimed, INC. | $276.60 | 2019-2020 | |
| Medtronic, INC. | $117.14 | 2021-2022 | |
| Abbott Laboratories | $97.17 | 2019-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $73.52 | 2022-2024 | |
| Pfizer INC. | $72.77 | 2023-2025 | |
| Sequel Med Tech, LLC | $40.33 | 2025 | Twiist |
| Beta Bionics, INC. | $37.12 | 2023-2024 | Ilet Bionic Pancreas |
| Merck Sharp & Dohme LLC | $32.52 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.18 | 2024 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $24.02 | 2023 | Strensiq |
| Tolmar Pharmaceuticals, INC. | $23.91 | 2022 | |
| Zealand Pharma US, INC. | $23.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.76 | 2024 | Flumist Quadrivalent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $20.83 | 2022 | |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Azurity Pharmaceuticals, INC. | $18.86 | 2024 | Triptodur |
| Dexcom, INC. | $18.58 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $17.08 | 2022 | |
| Biomarin Pharmaceutical INC. | $16.76 | 2024 | Voxzogo 1.2mg |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Buggs-Saxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.